Annexon(ANNX) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones Single, Well-Tolerated Infusion of ANX005 Significantly Accelerated Recovery of GBS Patients vs. Placebo in Pivotal Phase 3 Trial; Potential to be First Targeted Therapy for GBS; Topline Real-World Evidence (RWE) Comparability Data Now Expected by Year-End 2024 Dosing Initiated in ARCHER II Registrational Trial for ANX007; Only Program to Demonstrate Significant Vision Protection and Structural P ...